Inotrem
Targeting TREM-1 to restore immune balance
Paris, France · Founded 2013 · $229.3M raised
- Headquarters
- Paris
- Employees
- 11–50
- Founded
- 2013
- Business Model
- B2B
- Website
- inotrem.com
- Total Funding
- $229.3M
- Last Round
- $49.0M GrantNov 2021
- Rounds
- 5
About
Inotrem is a French clinical-stage biopharmaceutical company founded in 2013 specializing in immunotherapy for acute and chronic inflammatory syndromes, including sepsis. The company has developed a TREM-1 inhibition platform and lead compound nangibotide, and maintains offices in Paris and a technology center in Nancy, France.
Summary
Inotrem is a Biotech company based in Paris, France, founded in 2013. It has raised $229.3M in total across 5 rounds, most recently a $49.0M Grant round in Nov 2021. Investors include Bpifrance, Fountain Healthcare Pa and Morningside Group.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2021
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company